Despite these differences in the impact of trametinib on the viability in the RAS/MAPK pathway-altered neuroblastoma cell line panel, trametinib was able to decrease ERK phosphorylation in each of the cell lines studied (Figure 2B). The gene discussed is MAPK1; the disease is neuroblastoma.